Probiotics and Prebiotics as Dietary Supplements for the Adjunctive Treatment of Type 2 Diabetes-Reference-Cited by-同舟云学术

Probiotics and Prebiotics as Dietary Supplements for the Adjunctive Treatment of Type 2 Diabetes

Published:2023-03-01 Issue:1 Volume:72 Page:3-9
ISSN:2544-4646
Container-title:Polish Journal of Microbiology
language:en
Short-container-title:

Author:

WANG YUYING¹²,WEN LINA¹²,TANG HUAZHEN¹²,QU JINXIU¹²,RAO BENQIANG¹²

Affiliation:

1. Department of Gastrointestinal Surgery, Beijing Shijitan Hospital , Capital Medical University , Beijing , China

2. Key Laboratory of Cancer FSMP for State Market Regulation, Beijing Shijitan Hospital , Beijing , China

Abstract

Abstract In modern lifestyles, high-fat diets and prolonged inactivity lead to more people developing type 2 diabetes (T2D). Based on the modern pathogenesis of T2D, food, and its components have become one of the top concerns for patients. Recent studies have found that dysbiosis and gut-related inflammation are more common in T2D patients. Probiotics and prebiotics play complementary roles in the gut as dietary supplements. Together, they may help improve dysbiosis and intestinal inflammation in people with T2D, increase the production of blood glucose-lowering hormones such as incretin, and help reduce insulin resistance and lower blood glucose. Therefore, changing the dietary structure and increasing the intake of probiotics and prebiotics is expected to become a new strategy for the adjuvant treatment of T2D.

Publisher

Polish Society of Microbiologists

Subject

Microbiology (medical),Applied Microbiology and Biotechnology,General Medicine,Microbiology

Link

https://www.sciendo.com/pdf/10.33073/pjm-2023-013

Reference58 articles.

1. AL-Dulaimi M, Algburi A, Abdelhameed A, Mazanko MS, Rudoy DV, Ermakov AM, Chikindas ML. Antimicrobial and anti-biofilm activity of polymyxin E alone and in combination with probiotic strains of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 against clinical isolates of selected Acinetobacter spp.: a preliminary study. Pathogens. 2021 Dec;10(12):1574. https://doi.org/10.3390/pathogens10121574

2. Balaich J, Estrella M, Wu G, Jeffrey PD, Biswas A, Zhao L, Korennykh A, Donia MS. The human microbiome encodes resistance to the antidiabetic drug acarbose. Nature. 2021 Dec; 600(7887): 110–115. https://doi.org/10.1038/s41586-021-04091-0

3. Bock PM, Telo GH, Ramalho R, Sbaraini M, Leivas G, Martins AF, Schaan BD. The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2021 Jan;64(1):26–41. https://doi.org/10.1007/s00125-020-05295-1

4. Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016 Feb;39(2):198–205. https://doi.org/10.2337/dc15-0488

5. Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019 May;15(5):261–273. https://doi.org/10.1038/s41574-019-0156-z

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gut–Liver–Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies;Biomedicines;2024-06-24

2. AG1® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the Simulator of Human Intestinal Microbial Ecosystem® Model;Current Issues in Molecular Biology;2024-01-05

3. Attenuation of Hyperglycemia in Diabetic Rats Assisted by Immobilized Probiotic in Sodium Alginate;Probiotics and Antimicrobial Proteins;2023-10-10